Phadia AB - Strategic Analysis Review

Document Sample
Phadia AB - Strategic Analysis Review Powered By Docstoc
					                                         Phadia AB - Strategic Analysis Review

       Reference Code: GDME7255SA                                                                                        Publication Date: JUL 2010

       P.O. Box 6460                          Phone             +46 18 165000                          Revenue           3,451 (million SEK)
       Uppsala                                Fax               +46 18 140358                          Net Profit        NA
       SE-751 37                              Website           www.phadia.com                         Employees         1,351
       Sweden                                 Exchange                                                 Industry          Medical Equipment

      Company Overview
       Phadia AB (Phadia) is a medical device company engaged in the development, manufacturing and distribution of complete blood
       test systems for the diagnosis and monitoring of allergy, asthma and autoimmune diseases. Its product portfolio includes allergy
       blood testing reagents and automated instrumentation, which are used in laboratories and hospitals. The company also provides
       EliA, an automated system for the measurement of autoantibodies; Varelisa for the detection of autoantibodies; assays to support
       the diagnosis of celiac diseases; ImmunoCAP for measuring IgE antibodies; and ImmunoCAP Rapid Reader, used to aid in the
       diagnosis of allergy in a physician's office.

      Key Executives                                               SWOT Analysis
                 Name                         Title                Phadia AB, SWOT Analysis
      Magnus Lundberg              Chief Executive Officer         Strengths                                  Weaknesses

      Daniel L. Peters             Chairman
                                                                   Strong Product Development                 Dependence on Customers
      Stuart McAlpine              Director                        Capabilities
      Supraj Rajagopalan           Director                                                                   Product Recalls
                                                                   Diversified Geographical Presence
      Lars Holmqvist               Director
      Source: Company Website, Primary and Secondary Research
      GlobalData
                                                                   Opportunities                              Threats

      Key Competitors                                              Growing Aged Population                    Rapid Technological Change
      Qiagen N.V.
                                                                   Growth in Emerging Economies               Changing Diagnostic Market
      Becton, Dickinson and Company                                                                           Conditions
      Beckman Coulter, Inc.
      Siemens Healthcare
      F. Hoffmann-La Roche Ltd.                                     Source: Company Website, Primary and Secondary Research
      Source: Company Website, Primary and Secondary Research       GlobalData
      GlobalData




      Recent Developments
      Feb 26, 2010:                           Phadia Plans To Continue Development Of Allergen Component
      Oct 01, 2009:                           Phadia Promotes David Esposito To US President An
				
DOCUMENT INFO
Description: Phadia AB (Phadia) is a medical device company engaged in the development, manufacturing and distribution of complete blood test systems for the diagnosis and monitoring of allergy, asthma and autoimmune diseases. Its product portfolio includes allergy blood testing reagents and automated instrumentation, which are used in laboratories and hospitals. The company also provides EliA, an automated system for the measurement of autoantibodies; Varelisa for the detection of autoantibodies; assays to support the diagnosis of celiac diseases; ImmunoCAP for measuring IgE antibodies; and ImmunoCAP Rapid Reader, used to aid in the diagnosis of allergy in a physician's office. Phadia AB Key Recent Developments Feb 26, 2010: Phadia Plans To Continue Development Of Allergen Component Oct 01, 2009: Phadia Promotes David Esposito To US President And General Manager Aug 11, 2009: Phadia Appoints Senior Vice President Of US, Sales And Marketing Apr 16, 2009: Phadia Reports Total Revenues Of SEK2.8 Billion In 2008 GlobalData’s Phadia AB - Strategic Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – GlobalData’s summarization of the company’s business strategy. - SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Ke
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.